Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V M Rivera

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
International Immunology|December 1, 2000
Aberrant T cell responses to myelin antigens during clinical exacerbation in patients with multiple sclerosisM V Tejada-Simon, Y C Zang, D Yang, et al.
Oral Diseases|April 9, 2010
Evaluation of a rapamycin-regulated serotype 2 adeno-associated viral vector in macaque parotid glandsC Zheng, A Voutetakis, M Metzger, et al.
Bioorganic & Medicinal Chemistry|October 24, 1998
Synthesis and activity of bivalent FKBP12 ligands for the regulated dimerization of proteinsT Keenan, D R Yaeger, N L Courage, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2009
Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxelC Sessa, D Tosi, L Viganò, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2000
A ligand-reversible dimerization system for controlling protein-protein interactionsC T Rollins, V M Rivera, D N Woolfson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 6, 2012
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcomaM M Mita, E Poplin, C D Britten, et al.
Neurology|September 25, 2003
Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculographyT C Frohman, E M Frohman, P O'Suilleabhain, et al.
Neurology|September 10, 2003
The utility of MRI in suspected MS [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyE M Frohman, D S Goodin, P A Calabresi, et al.
The New England Journal of Medicine|November 5, 2013
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasJ E Cortes, D-W Kim, J Pinilla-Ibarz, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
International Immunology|December 1, 2000
Aberrant T cell responses to myelin antigens during clinical exacerbation in patients with multiple sclerosisM V Tejada-Simon, Y C Zang, D Yang, et al.
Oral Diseases|April 9, 2010
Evaluation of a rapamycin-regulated serotype 2 adeno-associated viral vector in macaque parotid glandsC Zheng, A Voutetakis, M Metzger, et al.
Bioorganic & Medicinal Chemistry|October 24, 1998
Synthesis and activity of bivalent FKBP12 ligands for the regulated dimerization of proteinsT Keenan, D R Yaeger, N L Courage, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2009
Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxelC Sessa, D Tosi, L Viganò, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 15, 2000
A ligand-reversible dimerization system for controlling protein-protein interactionsC T Rollins, V M Rivera, D N Woolfson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 6, 2012
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcomaM M Mita, E Poplin, C D Britten, et al.
Neurology|September 25, 2003
Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculographyT C Frohman, E M Frohman, P O'Suilleabhain, et al.
Neurology|September 10, 2003
The utility of MRI in suspected MS [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyE M Frohman, D S Goodin, P A Calabresi, et al.
The New England Journal of Medicine|November 5, 2013
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasJ E Cortes, D-W Kim, J Pinilla-Ibarz, et al.
Pageof 9